Answers are grounded in this paper and cite their sources.
Analysis identifies DNA methylation patterns as predictors of type 2 diabetes in women with polycystic ovarian syndrome, suggesting new biomarker possibilities.
Women with polycystic ovarian syndrome (PCOS) are at significantly increased risk of type 2 diabetes mellitus. However, while studies have identified patient-related factors associated with diabetes risk in PCOS and others have explored epigenetic changes in women with PCOS and healthy controls, we are not aware of any examination of epigenetic changes as risk predictors for diabetes in those with PCOS. Here, we identify DNA methylation patterns that may predict future diabetes onset in women with PCOS. Methylation patterns in bisulphite-converted DNA from blood samples in six matched pairs of women with PCOS with and without diabetes were analysed by Illumina HumanMethylation450 BeadChip-arrays and validated by bisulphite-pyrosequencing. 19 differentially-methylated CpGs were identified (≥0.2 β-value change in the same direction in ≥5 matched pairs). Three candidates (cg11897887, cg02819655, and cg25542007) demonstrated the best clinical potential. This novel genome-wide DNA methylation analysis in a unique cohort of matched PCOS women with or without diabetes identified novel methylation biomarkers that offer potential for prediction of the future onset of diabetes in PCOS.
No takes yet. Share an insight, caveat, or question.
Kitchen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: